Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCAPE: Palmitoylethanolamide for Opioid Use Disorder
NCT05480072Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Nov 2022
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in opioid use disorder (OUD), sponsored by Brigham and Women's Hospital. Primary endpoint: stress-induced opioid craving visual analog scale at day 21. Started Nov 2022; status: completed.
02
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05480072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480072.